Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Principal Investigator: Dr Matthew Roberts
Clinical Research Associate: Liza Vergara (AKTN)
Trial Number: AKTN 08.01
Population: Dialysate patients aged over 50 years or under 18 years with a history of diabetes, MI, peripheral arterial disease or stroke
Final recruitment number: 72 (target of 150)
Intervention: Carvedilol (6.25-25mg) versus placebo, daily for 12 months
Primary outcome: Safety and tolerability of intervention as well as feasibility of recruitment
Results: The BLOCADE trial demonstrated the need for a very large pool of patients from which to recruit with greater international collaboration required. Results of the study have been published in the American Journal of Kidney Disease, and Nephrology.
Click here to view the Statistical Analysis Plan.